Discussion
Cutaneous vasculitis (CV) is defined as an inflammatory disorder affecting the small vessels of the dermis. Clinical manifestations are urticarial, papules, plaques, palpable purpura, ulcers, nodules and livedo. Cutaneous vasculitis is classified based on the type of inflammatory infiltrations on the biopsy specimen, and the size of the involved vessels, etc. The most important subtypes are neutrophilic vasculitis, lymphocytic vasculitis, necrotizing vasculitis, thrombosing vasculitis, eosinophilic vasculitis, and granulomatous vasculitis. CV could be part of a systemic vasculitis or occur separately and be self-limited. The most common etiologies are infections, autoimmune systemic disorders, malignancies, drugs, and vaccines. CV represents a self-limited course in most cases. Systemic corticosteroids and immunosuppressive agents might be required in severe and systemic diseases [1]. Different types of vasculitis have been reported as adverse events following immunization. Culprit vaccines are influenza, BCG, human papillomavirus, and hepatitis B vaccines [2]. CV has been associated with both Coronavirus disease-2019 (COVID-19), and SARS-CoV-2 vaccines [3, 4]. The inflammatory response triggered by the vaccine, and immune complex deposition within the vessels wall of the dermis have been described as the cause of this adverse event. The responsible antigen for such an immune reaction might be the vaccine component encoding SARS-CoV-2 spike glycoprotein [5]. In conclusion, LCV could be a possible adverse event of different SARS-CoV-2 vaccines. Clinicians and manufacturers should be aware of this adverse event.